Abstract
With the aim to address an undesired cardiac issue observed with our related compound in the recently disclosed novel series of renin inhibitors, further chemical modifications of this series were performed. Extensive structure-activity relationships studies as well as in vivo cardiac studies using the electrophysiology rat model led to the discovery of clinical candidate trans-adamantan-1-ol analogue 56 (DS-8108b) as a potent renin inhibitor with reduced potential cardiac risk. Oral administration of single doses of 3 and 10 mg/kg of 56 in cynomolgus monkeys pre-treated with furosemide led to significant reduction of mean arterial blood pressure for more than 12 h.
Copyright © 2013 Elsevier Ltd. All rights reserved.
MeSH terms
-
Administration, Oral
-
Animals
-
Antihypertensive Agents / chemical synthesis*
-
Antihypertensive Agents / pharmacokinetics
-
Antihypertensive Agents / pharmacology
-
Arrhythmias, Cardiac / prevention & control*
-
Arterial Pressure / drug effects
-
Female
-
Heart / drug effects*
-
Heart / physiopathology
-
Humans
-
Hypertension / drug therapy*
-
Hypertension / enzymology
-
Hypertension / physiopathology
-
Macaca fascicularis
-
Male
-
Organ Culture Techniques
-
Piperazines / chemical synthesis*
-
Piperazines / pharmacokinetics
-
Piperazines / pharmacology
-
Protease Inhibitors / chemical synthesis*
-
Protease Inhibitors / pharmacokinetics
-
Protease Inhibitors / pharmacology
-
Rabbits
-
Rats
-
Renin / antagonists & inhibitors*
-
Renin / chemistry
-
Renin / metabolism
-
Structure-Activity Relationship
Substances
-
Antihypertensive Agents
-
Piperazines
-
Protease Inhibitors
-
Renin